More about

Cytokine Release Syndrome

News
August 30, 2022
4 min read
Save

CAR-T will ‘play a very important role’ in multiple myeloma treatment landscape

CAR-T will ‘play a very important role’ in multiple myeloma treatment landscape

The FDA approval of the first ever chimeric antigen receptor T-cell therapy for multiple myeloma in 2021 laid the groundwork for others to follow.

News
August 27, 2021
3 min read
Save

COVID-19-driven shortage of tocilizumab may impact delivery of CAR T-cell therapy

COVID-19-driven shortage of tocilizumab may impact delivery of CAR T-cell therapy

The FDA has included tocilizumab among its list of drugs currently in shortage.

News
April 22, 2021
2 min read
Save

Lenzilumab before CAR-T induces high response rates without severe toxicities

Lenzilumab before CAR-T induces high response rates without severe toxicities

A combination of lenzilumab and axicabtagene ciloleucel induced an 83% overall response rate among patients with advanced diffuse large B-cell lymphoma, according to topline data released by the agent’s manufacturer.

News
April 05, 2021
3 min read
Save

Anakinra shows promise as steroid-sparing agent for CAR T-cell therapy-related toxicities

Anakinra shows promise as steroid-sparing agent for CAR T-cell therapy-related toxicities

Steroids are commonly used to mitigate severe treatment-related adverse events associated with chimeric antigen receptor T-cell therapy.

News
March 10, 2021
3 min read
Save

Guidelines provide consensus on management of CAR T-cell therapy-related toxicities

Guidelines provide consensus on management of CAR T-cell therapy-related toxicities

The Society for Immunotherapy of Cancer published clinical practice guidelines on the management of toxicities related to the use of immune effector cell therapies, including chimeric antigen receptor T cells.

News
January 15, 2021
1 min watch
Save

VIDEO: CAR-T techniques could be applied to COVID-19 management

VIDEO: CAR-T techniques could be applied to COVID-19 management

Neetu Gupta, PhD, associate professor at Cleveland Clinic Foundation, discussed data comparing cytokine release syndrome in CAR T-therapy to COVID-19 at the ASH Annual Meeting and Exposition.

News
October 15, 2020
3 min read
Save

CAR-T-associated cardiac toxicity ‘limited and reversible’ in younger patients with ALL

CAR-T-associated cardiac toxicity ‘limited and reversible’ in younger patients with ALL

Cardiovascular toxicity associated with chimeric antigen receptor T-cell therapy is both limited and reversible among high-risk children and young adults with acute lymphoblastic leukemia, according to results of a phase 1 clinical trial.

News
September 24, 2020
3 min read
Save

CAR-T plus pembrolizumab shows ‘superior’ safety, promising responses in advanced lymphoma

CAR-T plus pembrolizumab shows ‘superior’ safety, promising responses in advanced lymphoma

No patients who received pembrolizumab with a CD19/CD22-directed chimeric antigen receptor T-cell therapy experienced high-grade cytokine release syndrome, according to phase 1 study findings presented during ESMO Virtual Congress 2020.

News
September 18, 2020
5 min read
Save

Limiting severe toxicity, mortality after CAR T-cell therapy

Limiting severe toxicity, mortality after CAR T-cell therapy

In this installment of In Practice, Marco L. Davila, MD, PhD, and Rawan G. Faramand, MD, of H. Lee Moffitt Cancer Center and Research Institute in Tampa, discuss the importance of developing a patient-specific management strategy to limit severe toxicities and mortality after chimeric antigen receptor T-cell therapy.

News
August 18, 2020
2 min read
Save

Frantic search for COVID-19 cure gives rise to ‘Wild West’ of clinical trials

Frantic search for COVID-19 cure gives rise to ‘Wild West’ of clinical trials

Keeping pace with the worldwide “deluge” of clinical trial developments pertaining to COVID-19 can be a full-time job, according to a presenter at the 2020 Association of Women in Rheumatology National Conference.

View more